Heart Failure/Transplantation
ESC Consensus Statement | Inotropic therapy in patients with advanced heart failure
15 Mar, 2023 | 15:14h | UTC
SR | Myocardial revascularization in patients with ischemic cardiomyopathy: for whom and how
14 Mar, 2023 | 13:46h | UTC
Burden, trends, and inequalities of heart failure globally, 1990 to 2019
14 Mar, 2023 | 13:35h | UTC
M-A | Opioids for breathlessness in heart failure have no significant benefits and increase adverse effects
9 Mar, 2023 | 14:11h | UTCSummary: The study aimed to assess the effectiveness of opioids in treating breathlessness in patients with heart failure and to evaluate their adverse effects. The authors conducted a systematic review of randomized controlled trials (RCTs) and included eight studies with 271 patients.
The results showed that opioids did not provide significant benefits in managing breathlessness in advanced HF and significantly increased the risk of adverse events such as nausea, vomiting, and constipation.
The authors suggest that opioids should be considered only as a last resort when other interventions have failed or in emergency situations.
Article: Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis – Heart
#ACC23 – RCT | Five-year follow-up after transcatheter repair of secondary mitral regurgitation
6 Mar, 2023 | 14:28h | UTCFive-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
COAPT at 5 Years: MitraClip Still Ahead, but Deaths and Crossovers Cast Shadows – TCTMD
Commentary on Twitter
Transcatheter repair of secondary mitral regurgitation for heart failure was associated with a lower rate of hospitalization for heart failure and lower all-cause mortality than medical therapy at 5 years of follow-up.
Full COAPT trial: https://t.co/rcJ6RQEMAX #ACC23/#WCCardio pic.twitter.com/sM8R50oaBq
— NEJM (@NEJM) March 5, 2023
Guideline | Acute mechanical circulatory support
27 Feb, 2023 | 13:04h | UTC
[Not published yet] M-A | Too little sodium can be harmful to heart failure patients
24 Feb, 2023 | 13:59h | UTCSummary: New research presented at the American College of Cardiology’s annual scientific session suggests that heart failure patients restricting their dietary sodium intake to levels below the standard recommended maximum of 2.3 grams per day do not have additional benefits and may be at increased risk of death. The study analyzed nine randomized controlled trials that assessed different levels of sodium restriction and found that patients following a diet with a sodium intake target below 2.5 grams per day were 80% more likely to die than those following a diet with a target of 2.5 grams per day or more. The researchers recommend establishing a safe level of sodium consumption instead of overly restricting sodium.
News release: Too Little Sodium Can be Harmful to Heart Failure Patients – American College of Cardiology
Worsening heart failure: nomenclature, epidemiology, and future directions
15 Feb, 2023 | 16:06h | UTC
Cohort Study | Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
15 Feb, 2023 | 15:59h | UTCSummary: The CardioRenal and Metabolic disease (CaReMe) HF study estimated the prevalence, clinical outcomes, and costs of heart failure (HF) across 11 countries using digital healthcare systems. The study found that the prevalence of HF was 1-2%, with the most frequent comorbidities being ischemic heart disease and chronic kidney disease (CKD) stages III– V.
Furthermore, the study revealed that hospital care costs were highest for cardiorenal diseases, even higher than those stemming from atherosclerotic cardiovascular diseases. This emphasizes the urgent need for improved risk management and healthcare planning for patients with HF, particularly those with cardiorenal complications.*
News Release: Up to 2% of adults in Europe, North America, Israel likely have heart failure – BMJ Newsroom
Commentary: Multinational Study Details Contemporary Prevalence, Treatment Strategies of Heart Failure – HCP Live
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Phase 2 RCT | Aficamten in patients with obstructive hypertrophic cardiomyopathy
14 Feb, 2023 | 10:37h | UTC
Consensus Statement | Evaluation and management of patients with diabetes and heart failure
10 Feb, 2023 | 13:51h | UTCRelated:
ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison – ESC Heart Failure
#ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Crossover RCT | Effects of SGLT2 inhibition on sodium in patients with chronic syndrome of inappropriate antidiuresis
8 Feb, 2023 | 12:34h | UTC
Commentary on Twitter
The syndrome of inappropriate antidiuresis (SIAD) is a major cause of hypotonic hyponatremia. This study shows the SGLT2 inhibitor empagliflozin is a promising new treatment for chronic SIAD-induced hyponatremia, possibly improving neurocognitive function https://t.co/U26RNmVM9j pic.twitter.com/8pH6xqSs7D
— JASN_News (@JASN_News) December 12, 2022
M-A | Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure
3 Feb, 2023 | 14:23h | UTC
Diagnostic accuracy study | Natriuretic peptide testing and heart failure diagnosis in primary care
3 Feb, 2023 | 14:04h | UTC
Heart failure: an update from the last years and a look at the near future
2 Feb, 2023 | 14:48h | UTCHeart failure: an update from the last years and a look at the near future – ESC Heart Failure
Cardiogenic Shock | Emergency department-focused management
25 Jan, 2023 | 11:21h | UTCCardiogenic Shock: Emergency Department-Focused Management – emDocs
Related: The medical treatment of cardiogenic shock – Journal of Intensive Medicine
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis
24 Jan, 2023 | 14:29h | UTCKey Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology
Commentary on Twitter
.@ACCinTouch's ? Expert Consensus Decision Pathway provides practical and timely guidance on the diagnosis and management of cardiac #amyloidosis, with an emphasis on comprehensive multidisciplinary care.
Learn more: https://t.co/1SunbtuQpO#JACC #CardioOnc #CardioTwitter pic.twitter.com/DLvFUpajHC
— JACC Journals (@JACCJournals) January 23, 2023
Review | Getting ahead of the game: in-hospital initiation of HFrEF therapies
20 Jan, 2023 | 14:24h | UTC
Cohort Study | Left atrial mechanical dysfunction and risk of ischemic stroke in people without atrial fibrillation
20 Jan, 2023 | 14:23h | UTCLeft Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke: A Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries:
Left Atrial Dysfunction and Risk for Ischemic Stroke – American College of Cardiology
Left Atrial Dysfunction Tied to Cerebral Infarcts in Absence of Prior AF, Stroke – TCTMD
Left Atrial Reservoir Strain Plus CHA₂DS₂-VASc Ups Stroke Prediction – HealthDay
Commentary on Twitter
A study of persons without a history of #AtrialFibrillation or #stroke has found that measuring left atrial mechanical function can improve stroke prediction. https://t.co/QEYHRFDPop @Maheshwari_EP @PennStHershey pic.twitter.com/pIutPcW5Sm
— Annals of Int Med (@AnnalsofIM) December 20, 2022
RCT | No difference in survival with Torsemide vs. Furosemide after discharge of patients hospitalized with heart failure
19 Jan, 2023 | 14:26h | UTCEffect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: TRANSFORM-HF—Can We Close the Loop on Diuretics in Heart Failure? – JAMA (free for a limited period)
News Release: Comparison of diuretics shows no difference in heart failure survival – NIH/National Heart, Lung and Blood Institute
Commentary on Twitter
Among patients discharged after hospitalization for heart failure, torsemide compared with furosemide did not result in a significant difference in all-cause mortality over 12 months. https://t.co/EwoVzRigkS pic.twitter.com/5dvhJ1oVaf
— JAMA (@JAMA_current) January 17, 2023
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments
17 Jan, 2023 | 13:08h | UTC
Commentary on Twitter
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments https://t.co/LCV8X0t4CZ @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/InOj7mDts7
— European Society of Cardiology Journals (@ESC_Journals) January 16, 2023
A multidisciplinary approach for the emergency care of patients with left ventricular assist devices
12 Jan, 2023 | 12:49h | UTC
Review | Predictors of early heart failure rehospitalization among older adults with preserved and reduced ejection fraction
11 Jan, 2023 | 13:58h | UTC
Cohort Study | Risk of heart failure in congenital heart disease
10 Jan, 2023 | 14:14h | UTCNews Release: Heart failure more common in heart defect survivors starting at young age – American Heart Association
The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies
9 Jan, 2023 | 14:10h | UTC
Commentary on Twitter
The Year in Cardiovascular Medicine 2022 series: the Top 10 papers in Heart Failure and Cardiomyopathies https://t.co/w6opcMPcBa@escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #HeartFailure #Cardiomyopathies pic.twitter.com/UrrX2LUQdI
— European Society of Cardiology Journals (@ESC_Journals) January 2, 2023